- Home
- RFM vs NRXP Comparison
RFM vs NRXP Comparison
Compare RFM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFM | NRXP |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 99.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | RFM | NRXP |
|---|---|---|
| Price | $14.86 | $3.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 12.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.68 | $1.65 |
| 52 Week High | $14.90 | $5.06 |
Technical Indicators
Market Signals| Indicator | RFM | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 68.43 | 51.92 |
| Support Level | $14.19 | $1.83 |
| Resistance Level | $14.87 | $4.20 |
| Average True Range (ATR) | 0.13 | 0.29 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 93.67 | 70.00 |
Price Performance
Historical ComparisonAbout RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.